2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2672

Serum Vitamin D Levels and Its Effect on Disease Activity and Fatigue in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2726

Severe Infections in Systemic Necrotizing Vasculitis: Incidence and Risk Factors

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 2243

Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2495

Sex Differences in the Achievement of Remission in Rheumatoid Arthritis – Choice of Disease Activity Measure Matters

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

9:00AM-11:00AM: Abstract Number: 2325

Sex Differences in the Association of Frailty and Bone Mineral Density in Patients with Rheumatoid Arthritis

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2365

Sex, Language and Age of Disease Onset Impact Illness Perceptions Among RA Patients

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2714

Significance of Anti-Neutrophil Cytoplasmic Antibodies in Systemic Sclerosis

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2593

Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis : Results from a Randomized, Double-Blind, Phase III Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2676

SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2655

SLE-Key® Ruleout Testing in Support of Patient Triage in the Clinical Rheumatology Setting

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2667

Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2643

Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2156

Smoking Status Predicts Earlier SLICC Damage Index Progression in a Large SLE Cohort

Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2372

Social Media Use for Health-Related Purposes By People with Rheumatic and Musculoskeletal Diseases – Results of a Global Survey

Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives

9:00AM-11:00AM: Abstract Number: 2505

Sociodemographic Factors Are Predictors of Poorer Clinical Outcome Trajectories in Early Rheumatoid Arthritis: Results from the Singapore Early Arthritis Cohort

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].